Effects of paricalcitol on biomarkers of inflammation and fibrosis in kidney transplant recipients: results of a randomized controlled trial
| Autor: | Jadranka Buturović-Ponikvar, Gregor Mlinšek, Miha Arnol, Aljoša Kandus, Manca Oblak |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Paricalcitol medicine.medical_specialty Randomization Urinary system Urology Placebo 01 natural sciences Plasma renin activity Renin-Angiotensin System 03 medical and health sciences Double-Blind Method Transforming Growth Factor beta medicine Clinical endpoint Humans 0101 mathematics Kidney transplantation Aged Inflammation Proteinuria Interleukin-6 business.industry General Medicine Middle Aged medicine.disease Fibrosis Kidney Transplantation 010101 applied mathematics 030104 developmental biology Nephrology Creatinine Ergocalciferols Female medicine.symptom business Biomarkers medicine.drug |
| Zdroj: | Clinical Nephrology. 88:119-125 |
| ISSN: | 0301-0430 |
| DOI: | 10.5414/cnp88fx26 |
| Popis: | AIMS Paricalcitol, a selective vitamin D activator, decreases proteinuria and may reduce graft failure risk in kidney transplant recipients. In this study, we evaluated the effect of paricalcitol on renin-angiotensin system (RAS) activity as well as interleukin (IL)-6 and transforming growth factor (TGF)-β plasma concentrations as biomarkers of inflammation and fibrosis. METHODS This placebo-controlled, double-blind trial enrolled a national cohort of kidney transplant recipients with urinary protein-to-creatinine ratio (UPCR) ≥ 20 mg/mmol despite optimization of the RAS blockade. Patients were randomly assigned to receive 24 weeks of treatment with 2 µg/day paricalcitol or placebo. The primary endpoint was the percent change in geometric mean UPCR. In this secondary analysis, we examined the effect of paricalcitol on plasma renin activity (PRA) and aldosterone levels as well as IL-6 and TGF-β plasma concentrations from baseline to last measurement during treatment. RESULTS Of the 168 patients with UPCR ≥ 20 mg/mmol who consented to undergoing randomization, 83 were allocated to paricalcitol and 85 to placebo. Baseline patient demographics, clinical characteristics, PRA, and aldosterone levels were similar between groups. Mean change in IL-6 was -29% (from 2.53 to 2.02 pg/mL) in the paricalcitol group and 23% (from 2.07 to 2.54 pg/mL) in the placebo group (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|